Level 42 AI

Level 42 AI is a Silicon Valley startup focused on leveraging software-defined hardware to capture and synchronize traditionally discarded or unobserved multi-modal data streams in order to predict and quantify health states. The company's goal is to address the unmet need for a fast, accurate, non-invasive, affordable mass screening test for COVID-19 and COVID-19-associated multi-system inflammatory syndrome in children (MIS-C). To achieve this, Level 42 AI is collaborating with prominent institutions such as Johns Hopkins School of Medicine and the University of California-San Francisco to conduct clinical studies and validate COVID-19 biosignatures. The innovative mass screening technology developed by Level 42 AI has the potential to remotely detect and screen individuals and patients with COVID-19 using non-invasive, non-intrusive, and non-contact technology. The company's AI algorithm deploys state-of-the-art machine learning techniques to differentiate early cellular and tissue mechano-transduction changes and the body's immune response to SARS-CoV-2 infection. By combining and analyzing multiple synchronized data streams, Level 42 AI aims to unveil robust biosignatures for actionable insights on various health conditions including COVID-19, MIS-C, asthma, COPD, cystic fibrosis, and more. Founded in 2019, the company operates in the AI, Health Care, Information Technology, Mobile, and Machine Learning industries. While details about the company's headquarters and recent investments are not available, Level 42 AI presents an innovative and potentially impactful approach to addressing critical health challenges, particularly in the context of the ongoing COVID-19 pandemic.